Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI

We presented a 67-year-old nonsmoking female lung adenocarcinoma patient with novel epidermal growth factor receptor (EGFR) A289G/F287_G288insHA cis mutations who responded positively to sintilimab combined with regorafenib and albumin paclitaxel, and sequential treatment of icotinib. Gene mutations...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, He, Dong, Weiwei, Zhao, Huixia, Hu, Yanyan, You, Xia, Sun, Tingting, Xiao, Wenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892601/
https://www.ncbi.nlm.nih.gov/pubmed/35251994
http://dx.doi.org/10.3389/fonc.2022.826938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892601/
https://www.ncbi.nlm.nih.gov/pubmed/35251994
http://dx.doi.org/10.3389/fonc.2022.826938

Ejemplares similares